AtheroNova completes dynamic treatment portion of Stage 1 clinical trial with AHRO-001 AtheroNova Inc le Cialis pour femme . , a biotech company centered on the study and development of substances to properly regress atherosclerotic plaque and improve lipid profiles in human beings, today announces accomplishment of a significant milestone with the completion of the energetic treatment part of its Phase 1 clinical trial using its lead substance, AHRO-001. The Stage 1 study objective would be to evaluate the security, tolerability and pharmacokinetics of AHRO-001 in healthful volunteers.
Atherosclerosis in menopause slowed by exercise and diet Thickening of artery wall space accelerates as females enter menopause, but these signals of the progression of atherosclerosis could be slowed by way of a lower-fat diet plan and increased exercise, according to a fresh research in the Aug. 4, 2004, problem of the Journal of the American University of Cardiology. About half the ladies took component in a way of living intervention program to lessen fat molecules and boost exercise, with a weight reduction objective of five to 15 pounds, based on their beginning weights.